AKT1 and breast cancer: DHA combined with trastuzumab, a specific inhibitor of the HER2 receptor, increased the efficacy of this drug in inhibiting the growth of Her2/neu positive breast cancer cells, by synergistically reducing the expression of the phosphorylated form of extracellular signal–regulated kinase (p-) and protein kinase B (p-AKT) [73].